GlassScriptPhysician profile
Michael S Frontiera
NPI 1669428017
$10,689.78
in general payments reported to CMS, 2019-2025
9 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $625 · 2021: $3,965 · 2022: $572 · 2023: $18.22 · 2024: $3,845 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,510 · Education: $18.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,510.00 |
| Education | $18.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,538.22 | 2021-2025 | Imfinzi |
| Kite Pharma, INC. | $1,700.00 | 2021 | |
| Taiho Oncology, INC. | $1,130.00 | 2024 | |
| Daiichi Sankyo INC. | $1,075.00 | 2022-2024 | Enhertu |
| Astellas Pharma US INC | $500.00 | 2021 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Frontiera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.